Hematocrit Effect on a Blood Glucose Monitor
Evaluation of the Hematocrit Effect on the Blood Glucose Monitor for Personal Use JT100
1 other identifier
interventional
1
1 country
1
Brief Summary
This study assesses the repeatability precision of a blood glucose monitoring system pursuant to ISO 15197
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus
Started Feb 2022
Shorter than P25 for not_applicable diabetes-mellitus
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2021
CompletedFirst Posted
Study publicly available on registry
December 15, 2021
CompletedStudy Start
First participant enrolled
February 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 22, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 14, 2022
CompletedJuly 28, 2022
July 1, 2022
Same day
December 2, 2021
July 26, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
repeatability precision
Assessment of the analytical measurement performance of the blood glucose monitor based on procedures defined in DIN EN ISO 15197
day 1
Study Arms (1)
Subject glucometer measurement
EXPERIMENTALInterventions
measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
Eligibility Criteria
You may qualify if:
- Male or female patients with clinical indication for blood glucose testing
- Signed form of consent
- Minimum age of 18 years
- Subjects are legally competent and capable to understand character, meaning and consequences of the study
You may not qualify if:
- Pregnancy or lactation
- Severe acute disease (at study physician's discretion)
- Acute or chronic diseases with inherent risk of aggravation by the procedure (at study physician's discretion)
- Current constitution that does not allow participating in the study (e.g. hematocrit out of
- the devices's specifications, medication known to influence blood glucose measurements; Appendix A of ISO 15197)
- Being unable to give informed consent
- Age younger than 18 years
- Legally incompetent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut für Diabetes Karlsburg GmbH
Karlsburg, Mecklenburg-Vorpommern, 17495, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Eckhard Salzsieder, PhD
Institut fur Diabetes Karlsburg GmbH
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, PhD
Study Record Dates
First Submitted
December 2, 2021
First Posted
December 15, 2021
Study Start
February 22, 2022
Primary Completion
February 22, 2022
Study Completion
March 14, 2022
Last Updated
July 28, 2022
Record last verified: 2022-07